Phathom Pharmaceuticals, Inc. PHAT Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion?
- Phathom Pharmaceuticals, Inc. (PHAT) reported deferred revenue, net of current portion of $347.9M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion increased by 1.2% year-over-year, from $343.81M to $347.9M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion?
- Over 3 years (2022 to 2025), Phathom Pharmaceuticals, Inc.'s deferred revenue, net of current portion has grown at a 47.3% compound annual growth rate (CAGR), from $109.53M to $350.12M.